ArticleFrontiers in microbiology2020
Heterologous Expression of the Class IIa Bacteriocins, Plantaricin 423 and Mundticin ST4SA, in
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Advancements in the Application of Ribosomally Synthesized and Post-Translationally Modified Peptides (RiPPs).Biomolecules · 2024Pooled it
- Weissella: A multifaceted genus making the way for next-gen biotherapeutics?Antonie van Leeuwenhoek · 2026Review
- Expression of Enterocin A in Saccharomyces cerevisiae.Probiotics and antimicrobial proteins · 2026Article
- Bacterial contamination in starch-to-ethanol fermentations: Can bacteriocin-producing Saccharomyces cerevisiae offer a solution?Journal of industrial microbiology & biotechnology · 2026Review
- Article
- Tandem solubility enhancing tags enable the heterologous expression andFrontiers in microbiology · 2026Article
- Expression of Caseicin from Lacticaseibacillus casei and Lacticaseibacillus zeae Provides Insight into Antilisterial Class IIa Bacteriocins.Probiotics and antimicrobial proteins · 2025Article
- Different Detection Strategies of Pediocin-Like Produced by Pediococcus pentosaceus.Probiotics and antimicrobial proteins · 2025Article
- Bactofencin YH, a novel bacteriocin with high inhibitory activity against clinical Streptococcus species.World journal of microbiology & biotechnology · 2024Article
- Heterologous Expression of Plantaricin 423 and Mundticin ST4SA in Saccharomyces cerevisiae.Probiotics and antimicrobial proteins · 2024Article
- The Progress of the Biotechnological Production of Class IIa Bacteriocins in Various Cell Factories and Its Future Challenges.International journal of molecular sciences · 2024Review
- Use of the mCherry fluorescent protein to optimize the expression of class I lanthipeptides in Escherichia coli.Microbial cell factories · 2023Article
- Heterologous expression of pediocin/papA in Bacillus subtilis.Microbial cell factories · 2022Article
- Pan-genomic and comparative analysis ofComputational and structural biotechnology journal · 2022Article
- Therapeutic Application of Lantibiotics and Other Lanthipeptides: Old and New Findings.Applied and environmental microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antilisterial class IIa bacteriocins, plantaricin 423 and mundticin ST4SA, have previously been purified from the cell-free supernatants of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.